바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.61 No.2
Citation Share

Phase Ⅱ Study of Irinotecan Plus Cisplatin as First Line therapy in Extensive Small-Cell Lung Cancer

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2006, v.61 no.2, pp.143-149









& (2006). Phase Ⅱ Study of Irinotecan Plus Cisplatin as First Line therapy in Extensive Small-Cell Lung Cancer. Tuberculosis & Respiratory Diseases, 61(2), 143-149.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background: Irinotecan (topoisomerase I inhibitor) is effective as a monotherapy against small-cell lung cancer(SCLC). Cisplatin is also an important drug against SCLC. A phase II study of irinotecan combined with cisplatin was carried out to evaluate the efficacy and toxicity of this combined regimen as a first line treatment in patients with extensive SCLC. Methods: Thirty-nine patients with previously untreated extensive SCLC were enrolled in this study. Irinotecan 60mg/㎡ was administered intravenously on days 1, 8 and 15, and in combination with cisplatin 60mg/㎡ on day 1 and every 28 days thereafter. Four cycles of chemotherapy were given to the patients. Results: The overall response rate was 77% with a complete response (CR) rate of 8%. The median survival time, 1- and 2-year survival rate were 14.8 months, 60.9% and 27.6%, respectively. The median progression free survival time, 6-and 12-month progression free survival rate were 8.4 months, 75% and 18.8%, respectively. The WHO grade 3 or more toxicity encountered were leukopenia (23%), diarrhea (26%). Two patients changed their chemotherapeutic regimen and one patient died from severe diarrhea. Conclusion: The combination of irinotecan and cisplatin is effective as a first line therapy in extensive SCLC is effective , but has severe or fatal diarrhea as toxicity. (Tuberc Respir Dis 2006; 61: 143-149)

keywords
Small-cell lung cancer, Irinotecan, Cisplatin., Small-cell lung cancer, Irinotecan, Cisplatin.

Reference

1.

Jeong ET, (2000) Clinical survey of lung cancer in Korea,

2.

Witta SE, (2005) chemotherapy for small cell lung cancer, Lippincott Williams and Wilkins

3.

Nitta K, Antitumor activity of 7-ethyl- 10-[4- a novel water-soluble derivative of camptothecin against murine tumors,

4.

Masuda N, (1992) CPT-11:A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer,

5.

Fujiwara Y, (1998) Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer,

6.

Noda K, (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer,

7.

No, (1979) WHO handbook for reporting the results of cancer treatment,

8.

Roth BJ, (jclinoncol1992) Randomized study of cyclophosphamide and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer a phase III trial of the Southeastern Cancer Study Group,

9.

Chute JP, (1999) Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer:perceptible progress,

10.

Hsiang YH, (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I,

11.

Masuda N, Phase I study of weekly intravenous infusions of CPT-11 a new derivative of camptothecin in the treatment of advanced non-small -cell lung cancer,

12.

Hanna N, (2006) Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer,

13.

Ihde DC, (1994) Prospective randomized comparison of high dose and standard dose etoposide and cisplatin chemotherapy on patients with extensive stage small cell lung cancer,

14.

Beutler E, (1998) Racial variability in the UDP-glucuronosyltransferase 1 a balanced polymorphism for regulation of bilirubin metabolism,

15.

Font A, (2001) UGT1A1 genotyping correlates with toxicity and survival in non-small cell lung cancer(NSCLC)patients treated with second- line CPT-11/docetaxel,

16.

Han JY, (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients With non-small-cell lung cancer treated with irinotecan and cisplatin,

17.

Jeong HL, (2005) Phase II trial of irinotecan plus cisplatin combinations on first line therapy for patients with small cell lung cancer,

Tuberculosis & Respiratory Diseases

e-Submission OA Policy